Please login to the form below

Not currently logged in

Boehringer files Pradaxa for new VTE indication in Europe

Seeks to add to anticoagulant’s approvals

Boehringer Ingelheim Pradaxa dabigatran pack

Boehringer Ingelheim has filed for approval of its anticoagulant Pradaxa for the treatment and prevention of venous thromboembolism (VTE) in Europe.

Specifically, the pharma company has submitted Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

If approved the new indication will boost the patient population addressed by the thrombin inhibitor, which is already registered for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the primary prevention of venous thromboembolic events in patients undergoing elective total hip replacement or total knee replacement surgery.

The submission is based on the results of four trials which have shown that the drug is as effective as warfarin in treating and preventing DVT and PE, but is associated with fewer bleeding complications.

VTE opens up a big new market for Pradaxa, as it affects around 2.5 million patients every year in the US and EU, with two-thirds of cases in institutionalised patients.

Meanwhile, annual costs are estimated to be more than €3bn in Europe for total direct costs associated with VTE and up to $15.5bn in the US for diagnosis and treatment of DVT and PE, according to Boehringer.

Approval would also help Boehringer as it jostles in the marketplace with other oral anticoagulants such as Bayer's Xarelto (rivaroxaban) and Bristol-Myers Squibb and Pfizer's Eliquis (apixaban), both Factor Xa inhibitors, which are also positioned as safer and easier-to-administer alternatives to warfarin.

Opinions differ on the eventual outcome of the three-way battle, although a number of analysts have out Eliquis out in front with around 60 per cent of the market, with Pradaxa and Xarelto fighting over the remainder.

Xarelto was approved for PE and DVT prevention last year, while Eliquis has not yet been submitted for approval in this setting, although it recently showed efficacy in the AMPLIFY-EXT trial as a long-term VTE therapy.

25th June 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....